Cooper C. Collins
CIK 1485508 · Chief Strategic Officer · last filed 2025-11-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MAGNOLIA, TX 77354
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TXMD | Director | 60,516 | $1.80 | $108.9K | -$2.99M | 24 | 2025-11-05 |
| PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Chief Strategic Officer | 298,073 | — | — | -$16.74M | 12 | 2014-03-05 |
Recent Filings · Page 3 of 4
37 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-03-26 | TXMD | Grant (A) | — | $0 | EDGAR |
| 2014-03-05 | PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Sell (S) | −3,590,000 | -$12.22M | EDGAR |
| 2014-02-05 | PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Sell (S) | −90,000 | -$199.7K | EDGAR |
| 2014-01-08 | PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Sell (S) | −27,962 | -$61.6K | EDGAR |
| 2014-01-08 | TXMD | Exer (X) | — | $0 | EDGAR |
| 2014-01-06 | PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Sell (S) | −62,038 | -$145.7K | EDGAR |
| 2013-12-10 | PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Sell (S) | −37,452 | -$86.6K | EDGAR |
| 2013-12-04 | PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Sell (S) | −52,548 | -$128.2K | EDGAR |
| 2013-11-05 | PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Sell (S) | −90,000 | -$180.6K | EDGAR |
| 2013-10-08 | PERNIX THERAPEUTICS HOLDINGS, INC. (PTX) Delisted | Sell (S) | −23,364 | -$57.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.